WHO ICTRP trial
The efficacy and safety of rabeprazole sodium 20mg against reflux esophagitis…
JPRN-UMIN000020701 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000020701 |
|---|---|
| Public title | The efficacy and safety of rabeprazole sodium 20mg against reflux esophagitis associated with systemic scleroderma |
| Scientific title | The efficacy and safety of rabeprazole sodium 20mg against reflux esophagitis associated with systemic scleroderma - The efficacy and safety of rabeprazole sodium 20mg against reflux esophagitis associated with systemic scleroderma |
| Primary sponsor | Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not applicable |
| Countries | Japan |
| Conditions | reflux esophagitis associated with systemic scleroderma |
| Interventions | Rabeprazole sodium 1 tablet a day will be added to subjects whose symptom does not improve with 1 tablet a day. The study will continue until subjects meet discontinuance criteria. |
| Registration date | Jan 22, 2016 |
| Target size | 40 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: